Trixeo Aerosphere receives positive CHMP opinion
19 October 2020 07:00 BST Trixeo Aerosphere recommended for approval in the EUby CHMP for the maintenance treatment of COPD Recommendation of triple-combination therapy based onpositive results from ETHOS and KRONOS Phase III trials AstraZeneca's Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been recommended for marketing authorisation in the European Union (EU) for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled